Literature DB >> 26834055

Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter.

Chau T Dang1, Anthony F Yu2, Lee W Jones2, Jennifer Liu2, Richard M Steingart2, Daniel F Argolo2, Larry Norton2, Clifford A Hudis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26834055      PMCID： PMC5070558          DOI： 10.1200/JCO.2015.64.5515

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

1.  Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

Authors:  A D Seidman; M N Fornier; F J Esteva; L Tan; S Kaptain; A Bach; K S Panageas; C Arroyo; V Valero; V Currie; T Gilewski; M Theodoulou; M E Moynahan; M Moasser; N Sklarin; M Dickler; G D'Andrea; M Cristofanilli; E Rivera; G N Hortobagyi; L Norton; C A Hudis
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

2.  Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.

Authors:  Pooja P Advani; Karla V Ballman; Travis J Dockter; Gerardo Colon-Otero; Edith A Perez
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

3.  Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer.

Authors:  Mariana Chavez-MacGregor; Jiangong Niu; Ning Zhang; Linda S Elting; Benjamin D Smith; Jose Banchs; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

4.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

5.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.

Authors:  Jersey Chen; Jessica B Long; Arti Hurria; Cynthia Owusu; Richard M Steingart; Cary P Gross
Journal:  J Am Coll Cardiol       Date:  2012-11-14       Impact factor: 24.094

8.  Natural history of asymptomatic left ventricular systolic dysfunction in the community.

Authors:  Thomas J Wang; Jane C Evans; Emelia J Benjamin; Daniel Levy; Elizabeth C LeRoy; Ramachandran S Vasan
Journal:  Circulation       Date:  2003-08-11       Impact factor: 29.690

9.  Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Sandra M Swain; Michael S Ewer; Javier Cortés; Dino Amadori; David Miles; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; José Baselga
Journal:  Oncologist       Date:  2013-03-08

10.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544
View more
  34 in total

1.  Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.

Authors:  Nishant Mohan; Jiangsong Jiang; Milos Dokmanovic; Wen Jin Wu
Journal:  Antib Ther       Date:  2018-08-31

2.  Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.

Authors:  Mariana L Henry; Jiangong Niu; Ning Zhang; Sharon H Giordano; Mariana Chavez-MacGregor
Journal:  JACC Cardiovasc Imaging       Date:  2018-08

3.  Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada.

Authors:  Moira Rushton; Isac Lima; Meltem Tuna; Chris Johnson; Josee Ivars; Kathy Pritchard; Steven Hawken; Susan Dent
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

Review 4.  Cardiotoxicity of Contemporary Breast Cancer Treatments.

Authors:  Katherine Lee Chuy; Anthony F Yu
Journal:  Curr Treat Options Oncol       Date:  2019-05-09

Review 5.  The connection between the breast and heart in a woman: Breast cancer and cardiovascular disease.

Authors:  Martha Gulati; Sharon L Mulvagh
Journal:  Clin Cardiol       Date:  2018-02-15       Impact factor: 2.882

Review 6.  Advances in the management of HER2-positive early breast cancer.

Authors:  José Baselga; Robert E Coleman; Javier Cortés; Wolfgang Janni
Journal:  Crit Rev Oncol Hematol       Date:  2017-10-04       Impact factor: 6.312

7.  Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study.

Authors:  Monica Tang; Andrea L Schaffer; Belinda E Kiely; Benjamin Daniels; Chee K Lee; Robert J Simes; Sallie-Anne Pearson
Journal:  Breast Cancer Res Treat       Date:  2021-02-22       Impact factor: 4.872

Review 8.  Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity.

Authors:  Lars Michel; Tienush Rassaf; Matthias Totzeck
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

Review 9.  Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.

Authors:  Daniel Lenihan; Joseph Carver; Charles Porter; Jennifer E Liu; Susan Dent; Paaladinesh Thavendiranathan; Joshua D Mitchell; Anju Nohria; Michael G Fradley; Iskra Pusic; Keith Stockerl-Goldstein; Anne Blaes; Alexander R Lyon; Sarju Ganatra; Teresa López-Fernández; Rupal O'Quinn; Giorgio Minotti; Sebastian Szmit; Daniela Cardinale; Jose Alvarez-Cardona; Giuseppe Curigliano; Tomas G Neilan; Joerg Herrmann
Journal:  CA Cancer J Clin       Date:  2020-09-10       Impact factor: 508.702

10.  Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.

Authors:  Anya Litvak; Bhavina Batukbhai; Stuart D Russell; Hua-Ling Tsai; Gary L Rosner; Stacie C Jeter; Deborah Armstrong; Leisha A Emens; John Fetting; Antonio C Wolff; Raquel Silhy; Vered Stearns; Roisin M Connolly
Journal:  Cancer       Date:  2018-01-30       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.